The estimated Net Worth of Alexander Edward Iii Kuta is at least $2.75 Million dollars as of 7 March 2023. Alexander Kuta owns over 585 units of uniQure N.V stock worth over $494,384 and over the last 7 years he sold QURE stock worth over $902,572. In addition, he makes $1,353,030 as Executive Vice President and Operations at uniQure N.V.
Sign up
Alexander Kuta QURE stock SEC Form 4 insiders trading
Alexander has made over 29 trades of the uniQure N.V stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 585 units of QURE stock worth $12,496 on 7 March 2023.
The largest trade he's ever made was exercising 37,762 units of uniQure N.V stock on 27 July 2022 worth over $200,516. On average, Alexander trades about 4,595 units every 41 days since 2018. As of 7 March 2023 he still owns at least 90,381 units of uniQure N.V stock.
You can see the complete history of Alexander Kuta stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alexander Kuta biography
Dr. Alexander Edward Kuta Ph.D., III serves as Executive Vice President, Operations of the Company. Prior to joining uniQure, he was Vice President of Research & Development Global Regulatory Affairs for EMD Serono, responsible for immune-mediated diseases, oncology and biologics regulatory CMC, from January 2016 to September 2016. He joined EMD Serono in April 2013 as Vice President, Head of US Regulatory Affairs; while at EMD Serono he served on the US Leadership Team. From April 2012 to March 2013, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous industry experience includes senior regulatory leadership roles at AMAG Pharmaceuticals (NASDAQ: AMAG) from August 2010 to April 2012 as well as Genzyme Corporation from August 1995 to July 2010 where he worked in the areas of rare diseases, cell and gene therapy, therapeutic proteins and biomaterials. Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA from January 1993 to August 1995 and a Scientific Reviewer from January 1990 to January 1993. Dr. Kuta has served on the BIO Regulatory Affairs Leadership Committee - Cell and Gene Therapy Working Group, as reviewer for the National Gene Vector Laboratories program, on the ICH (M6) Gene Therapy Working Group and is currently on the scientific review board of the Gene Therapy Resource Program of NHLBI/NIH. Dr. Kuta holds a Bachelor of Science degree from Saint John’s University, Collegeville, MN and a Ph.D. from the Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/National Institutes of Health.
What is the salary of Alexander Kuta?
As the Executive Vice President and Operations of uniQure N.V, the total compensation of Alexander Kuta at uniQure N.V is $1,353,030. There are 2 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
How old is Alexander Kuta?
Alexander Kuta is 60, he's been the Executive Vice President and Operations of uniQure N.V since . There are 4 older and 11 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
What's Alexander Kuta's mailing address?
Alexander's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Insiders trading at uniQure N.V
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos, and William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
What does uniQure N.V do?
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
What does uniQure N.V's logo look like?
Complete history of Alexander Kuta stock trades at uniQure N.V
uniQure N.V executives and stock owners
uniQure N.V executives and other stock owners filed with the SEC include:
-
Matthew Kapusta,
Chief Executive Officer, Chief Financial Officer, Executive Director -
Robert Gut,
Executive Director -
Alexander Kuta,
Executive Vice President, Operations -
Maria Cantor,
Senior Vice President, Investor Relations and Communications -
Matthew Craig Kapusta,
CEO & Exec. Director -
Dr. Alexander E. Kuta Ph.D.,
Exec. VP of Quality & Regulatory -
Dr. Ricardo Dolmetsch Ph.D.,
Pres of R&D -
Christian Klemt,
CFO, Principal Financial Officer & GM of Amsterdam Site -
David Meek,
Non-Executive Independent Director -
Philip Astley-Sparke,
Independent Non-Executive Chairman of the Board -
Jack Kaye,
Non-Executive Independent Director -
Jeremy Springhorn,
Non-Executive Independent Director -
Madhavan Balachandran,
Non-Executive Independent Director -
Paula Soteropoulos,
Non-Executive Independent Director -
Leonard Post,
Director -
Ricardo Dolmetsch,
President, Research and Development -
Erin Boyer,
Chief People & Culture Office -
Richard Porter Ph.D.,
SVP of R&D and GM of Corlieve -
Dr. Tamara Tugal Ph.D., MBA,
Bus. Devel. Director -
Maria E. Cantor,
Chief Communications Officer -
David Cerveny,
Chief Legal Officer, Gen. Counsel & Sec. -
Pierre Caloz,
Chief Operating Officer -
Prof. Hugo Katus,
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -
Rachelle Suzanne Jacques,
Director -
Christian Meyer,
Chief Medical Officer -
Harald Petry,
Chief Scientific Officer -
Maiken Keson Brookes,
General Counsel -
Jonathan Garen,
Chief Business Officer -
David Schaffer,
Director -
Paul E Firuta,
Chief Commercial Officer -
William Lewis,
Director -
Steven Zelenkofske,
Chief Medical Officer -
Deventer Sander Van,
EVP, Research & Product Dev. -
Scott T. Mc Millan,
Chief Operating Officer -
Pierre Caloz,
Chief Operating Officer -
Christian Klemt,
Chief Financial Officer -
Jeannette Potts,
Chief Legal Officer -
Walid Abi Saab,
Chief Medical Officer